{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:59Z","timestamp":1792511399446,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study is to directly compare the effects of SGLT2 inhibitors and DPP-4 inhibitors on \u03b2-cell function in patients with type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We conducted a 26-week, randomized, open-label, parallel-group study, including a 1-2 week drug washout period, in patients with type 2 diabetes with HbA1c \u22657.0% and &amp;lt;9.0% and BMI \u226520 kg\/m<jats:sup>2<\/jats:sup> despite treatment with a drug na\u00efve or other than DPP-4 inhibitors or SGLT2 inhibitors. A total of 103 subjects were randomly assigned to receive once daily oral luseogliflozin (L) or teneligliptin (T). The primary endpoint was the effect of L vs. T on the change in logarithmus naturalis (Ln) disposition index (DI) (DI <jats:sub>0-120min<\/jats:sub>; combining measures of insulin secretion and sensitivity) from baseline to week 25-26 (post intervention), which was calculated by conducting an oral glucose tolerance test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ln DI <jats:sub>0-120min<\/jats:sub> were improved in both groups: -0.46 \u00b1 0.68 to -0.20 \u00b1 0.59 (<jats:italic>p<\/jats:italic>=0.03) in L group and -0.26 \u00b1 0.60 to -0.05 \u00b1 0.62 (<jats:italic>p<\/jats:italic>=0.01) in T group. The change in Ln serum proinsulin\/C-peptide ratio, a marker of \u03b2-cell dysfunction, was reduced in L group (1.63 \u00b1 0.63 to 1.56 \u00b1 0.68, <jats:italic>p<\/jats:italic>=0.16), but rather increased in T group (1.70 \u00b1 0.75 to 1.90 \u00b1 0.51, <jats:italic>p<\/jats:italic>=0.01), with significant difference between the two groups (-0.27; <jats:italic>p<\/jats:italic>=0.004).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Improvement of disposition index in subjects with obese type 2 diabetes was comparable between luseogliflozin and teneligliptin. On the other hand, it is likely that alleviation of \u03b2-cell dysfunction is more effective with luseogliflozin compared to tenegliptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/rctportal.niph.go.jp\/en<\/jats:uri>, identifier jRCTs061190008.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1412553","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:39:56Z","timestamp":1729485596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic \u03b2-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study)"],"prefix":"10.3389","volume":"15","author":[{"given":"Masashi","family":"Shimoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukino","family":"Katakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Mashiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Hirukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoatsu","family":"Mune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"Idf diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","unstructured":"The national health and nutrition survey2016"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2013.02.313","article-title":"Type 2 diabetes complications","volume":"42","author":"Schlienger","year":"2013","journal-title":"Presse Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v8.i4.120","article-title":"Type 2 diabetes and quality of life","volume":"8","author":"Trikkalinou","year":"2017","journal-title":"World J Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9349-0","article-title":"Determinants of mortality in patients with type 2 diabetes: A review","volume":"17","author":"Engelmann","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (Ukpds 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6898","article-title":"Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"343","author":"Hemmingsen","year":"2011","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto","year":"2013","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00037","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of dpp-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action","volume":"5","author":"Fujita","year":"2014","journal-title":"J Diabetes Investig"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.02.016","article-title":"Cardiometabolic effects of a new class of antidiabetic agents","volume":"37","author":"Desouza","year":"2015","journal-title":"Clin Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/srep44865","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials","volume":"7","author":"Lyu","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1507\/endocrj.EJ14-0335","article-title":"Ameliorated pancreatic \u03b2 Cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin","volume":"62","author":"Takahara","year":"2015","journal-title":"Endocr J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12005","article-title":"Vildagliptin preserves the mass and function of pancreatic \u03b2 Cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes","volume":"15","author":"Hamamoto","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.10.109","article-title":"Protective effects of sglt2 inhibitor luseogliflozin on pancreatic \u03b2-cells in obese type 2 diabetic db\/db mice","volume":"470","author":"Okauchi","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2007.s212","article-title":"Accurate assessment of beta-cell function: the hyperbolic correction","author":"Bergman","year":"2002","journal-title":"Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1441","article-title":"The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose","volume":"31","author":"Utzschneider","year":"2008","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2167-8","article-title":"Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: A randomised controlled trial","volume":"54","author":"Foley","year":"2011","journal-title":"Diabetologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/JME-12-0039","article-title":"Dpp4 inhibitor vildagliptin preserves \u03b2-cell mass through amelioration of endoplasmic reticulum stress in C\/ebpb transgenic mice","volume":"49","author":"Shimizu","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.08.006","article-title":"Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db\/db mice","volume":"64","author":"Wu","year":"2015","journal-title":"Metabolism"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00875.x","article-title":"Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia","volume":"10","author":"Scherbaum","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1029","article-title":"The dpp-4 inhibitor linagliptin restores \u03b2-cell function and survival in human isolated islets through glp-1 stabilization","volume":"98","author":"Shah","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e76713","DOI":"10.1371\/journal.pone.0076713","article-title":"Impact of three oral antidiabetic drugs on markers of \u03b2-cell function in patients with type 2 diabetes: A meta-analysis","volume":"8","author":"Lu","year":"2013","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.3390\/ijms23095104","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors on pancreatic \u03b2-cell mass and function","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1328","article-title":"Sglt2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13400","article-title":"Protective effects of the sglt2 inhibitor luseogliflozin on pancreatic \u03b2-cells in db\/db mice: the earlier and longer, the better","volume":"20","author":"Kimura","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9740","DOI":"10.1038\/s41598-022-13888-6","article-title":"Luseogliflozin preserves the pancreatic beta-cell mass and function in db\/db mice by improving mitochondrial function","volume":"12","author":"Yamauchi","year":"2022","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258054","article-title":"Sglt2 inhibitors therapy protects glucotoxicity-induced \u03b2-cell failure in a mouse model of human katp-induced diabetes through mitigation of oxidative and er stress","volume":"17","author":"Shyr","year":"2022","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.935764","article-title":"Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: A 24-week, randomized, double-blind, placebo-controlled, phase iii study","volume":"15","author":"Inagaki","year":"2014","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1412553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:40:07Z","timestamp":1729485607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1412553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":37,"alternative-id":["10.3389\/fendo.2024.1412553"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1412553","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"article-number":"1412553"}}